[A22-113] Remdesivir (COVID-19, requirement for additional oxygen supply, = 4 weeks - < 12 years of age) – Benefit assessment according to § 35a Social Code Book V
Last updated 16.01.2023
Project no.:
A22-113
Commission:
Commission awarded on 17.10.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
Children aged 4 weeks to 11 years and weighing at least 3 kg with COVID-19 and pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-04 | Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-38 | Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-112 | Remdesivir (COVID-19, without supplemental oxygen, < 18 years of age) – Benefit assessment according to § 35a Social Code Book V | Commission completed |